β-Lactamase inhibitors: Evolving compounds for evolving resistance targets

Expert Opinion on Investigational Drugs

Volumn 13, Issue 10, 2004, Pages 1307-1318

  Georgopapadakou, Nafsika H ^a  

^a METHYLGENE INC   (Canada)

Author keywords

lactamase inhibitors; lactamases; Carbapenemases; Cephem sulfones; Clavulanic acid; ESBLs; IMP 1 metallo lactamase; L1 metallo lactamase; OXA lactamase; Oxapenams; Oxapenems; PC1 lactamase; Penam sulfones; SHV lactamse; Sulbactam; Tazobactam; TEM lactamase

Indexed keywords

3 (4 AMINO 1,1 DIMETHYLBUTYL) 6 (1 HYDROXYETHYL)OXAPENEM 3 CARBOXYLIC ACID; 6 (1 METHYL 1,2,3 TRIAZOL 4 YLMETHYLENE)PENEM 3 CARBOXYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CEPHEM DERIVATIVE; CLAVULANIC ACID; MONOBACTAM; PENAM DERIVATIVE; PENEM DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RO 151903; SERINE DERIVATIVE; SULBACTAM; SULPERAZONE; SULTAMICILLIN; TAZOBACTAM; TICARCILLIN; TIMENTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; ENTEROBACTER; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; HUMAN; NONHUMAN; PSEUDOMONAS; REVIEW; STENOTROPHOMONAS;

ANIMALS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; ENZYME INHIBITORS; HUMANS; PENICILLANIC ACID; SULBACTAM;

EID: 5444244484     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.10.1307     Document Type: Review

References (128)

1. DURCKHEIMER W, BLUMBACH J, LATTRELL R, SCHEUNEMANN KH: Recent developments in the field of β-lactam antibiotics. Angew. Chem Int. Ed. Engl. (1985) 24: 180-202.
2. NEU HC: β-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. Rev. Infect. Dis. (1986) 8 (Suppl. 3):S237-S259.
3. GEORGOPAPADAKOU NH: Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob. Agents Chemother. (1993) 37: 2045-2053.
4. GOFFIN C, GHUYSEN JM: Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol. Mol. Biol. Rev. (1998) 62: 1079-1093.
5. BJORKMAN J, ANDERSSON DI: The cost of antibiotic resistance from a bacterial perspective. Drug Resist. Updat. (2000) 3: 237-245.
6. CHAMBERS HF: Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J. Infect. Dis. (1999)179 (Suppl. 2):S353-S359.
7. WU SW, DE LENCASTRE H, TOMASZ A: Recruitment of the mecA gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus. J. Bacteriol. (2001) 183: 2417-2424.
8. KNOX JR, MOEWS PC, FRERE JM: Molecular evolution of bacterial β-lactam resistance. Chem. Biol. (1996) 3: 937-947.
9. GEORGOPAPADAKOU NH, SYKES RB: Enzymes interacting with β-lactam antibiotics. In: Handbook of Experimental Pharmacology, (Volume 67-II). Antibiotics containing the β-lactam structure. AL Demain, NA Solomon (Eds), Springer-Verlag, Berlin Heidelberg, Germany (1983):1-77.
10. GHUYSEN JM: Serine β-lactamases and penicillin-binding proteins. Ann. Rev. Microbiol. (1991) 45: 37-67.
11. RICE LB, BONOMO RA: β-Lactamases: which ones are clinically important? Drug Resist. Updat. (2000) 3: 178-189.
12. THOMSON KS, SMITH MOLAND E: Version 2000: the new β-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect. (2000) 2: 1225-1235.
13. BUSH K: The impact of β-lactamases on the development of novel antimicrobial agents. Curr. Opin. Investig. Drugs (2002) 3 1284-1290.
14. HELFAND MS, BONOMO RA: β-Lactamases: a survey of protein diversity. Curr. Drug. Targets. Infect. Disord. (2003) 3: 9-23.
15. AMBLER RP: The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. (1980) 289: 321-331.
16. LEDENT P, RAQUET X, JORIS B, VAN BEEUMEN J, FRERE JM: A comparative study of class-D β-lactamases. Biochem. J. (1993) 292 (Pt 2):555-562.
17. BUSH K, JACOBY GA, MEDEIROS AA: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. (1995) 39: 1211-1233.
18. WALEY SG: An explicit model for bacterial resistance: application to β-lactam antibiotics. Microbiol. Sci. (1987) 4 143-146.
19. NIKAIDO H, NORMARK S. Sensitivity of Escherichia coli to various β-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic β-lactamases: a quantitative predictive treatment. Mol. Microbiol. (1987) 1: 29-36.
20. MARTINEZ-MARTINEZ L, HERNANDEZ-ALLES S, ALBERTI S, JACOBY GA: In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob. Agents Chemother. (1996) 40: 342-348.
21. LI XZ, ZHANG L, SRIKUMAR R, POOLE K: β-Lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1998) 42: 399-403.
22. FARMER TH, DEGNAN BA, PAYNE DJ: Penetration of β-lactamase inhibitors into the periplasm of Gram-negative bacteria. FEMS Microbiol. Lett. (1999) 176: 11-15.
23. BRADFORD PA: Extended-spectrum β-lactamases in the 21st century-characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. (2001) 14: 933-951.
24. POIREL L, KAMPFER P, NORDMANN P. Chromosome-encoded Ambler class A β-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Antimicrob. Agents Chemother. (2002) 46: 4038-4040.
25. LAGATOLLA C, TONIN EA, MONTI-BRAGADIN C et al.: Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-β-lactamase determinants in European hospital. Emerg. Infect. Dis. (2004) 10: 535-538.
26. ALVAREZ M, TRAN JH, CHOW N, JACOBY GA: Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob. Agents Chemother. (2004) 48: 533-537.
27. BERT F, BRANGER C, LAMBERT-ZECHOVSKY N: Comparative activity of β-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA β-lactamases. Chemotherapy (2004) 50: 31-34.
28. HERZBERG O: Refined crystal structure of β-lactamase from Staphylococcus aureus PC1 at 2.0 A resolution. J. Mol. Biol. (1991) 217: 701-719.
29. BANERJEE S, PIEPER U, KAPADIA G, PANNELL LK, HERZBERG O: Role of the omega-loop in the activity, substrate specificity, and structure of class A β-lactamase. Biochemistry (1998) 37: 3286-3296.
30. CHEN CC, HERZBERG O: Structures of the acyl-enzyme complexes of the Staphylococcus aureus β-lactamase mutant Glu166Asp:Asn170Gln with benzylpenicillin and cephaloridine. Biochemistry (2001) 40: 2351-2358.
31. STRYNADKA NC, ADACHI H, JENSEN SE et al.: Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis at 1.7 Å resolution. Nature (1992) 359: 700-705.
32. JELSCH C, MOUREY L, MASSON JM, SAMAMA JP: Crystal structure of Escherichia coli TEM1 β-lactamase at 1.8 Å resolution. Proteins (1993) 16: 364-383.
33. KNOX JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. (1995) 39: 2593-2601.
34. KUZIN AP, NUKAGA M, NUKAGA Y, HUJER AM, BONOMO RA, KNOX JR: Structure of the SHV-1 β-lactamase. Biochemistry (1999) 38: 5720-5327.
35. NUKAGA M, MAYAMA K, HUJER AM, BONOMO RA, KNOX JR: Ultrahigh resolution structure of a class A β-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol. (2003) 328: 289-301.
36. JUTEAU JM, BILLINGS E, KNOX JR, LEVESQUE RC: Site-saturation mutagenesis and three-dimensional modeling of ROB-1 define a substrate binding role of Ser130 in class A β-lactamases.Protein Eng. (1992) 5: 693-701.
37. TRANIER S, BOUTHORS AT, MAVEYRAUD L, GUILLET V, SOUGAKOFF W, SAMAMA JP: The high resolution crystal structure for class A β -lactamase PER-1 reveals the bases for its increase in breadth of activity. J. Biol. Chem. (2000) 275: 28075-28082.
38. SOUGAKOFF W, L'HERMITE G, PERNOT L et al.: Structure of the imipenem-hydrolyzing class A β-lactamase SME-1 from Serratia marcescens. Acta Crystallogr. D. Biol. Crystallogr. (2002) 58 (Pt 2): 267-274.
39. SWAREN P, MAVEYRAUD L, RAQUET X et al.: X-ray analysis of the NMC-A β-lactamase at 1.64-Å resolution, a class A carbapenemase with broad substrate specificity. J. Biol. Chem. (1998) 273: 26714-26721.
40. MOUREY L, KOTRA LP, BELLETTINI J et al.: Inhibition of the broad spectrum non-metallo-carbapenamase of class A (NMC-A) β-lactamase from Enterobacter cloacae by monocyclic β -lactams. J. Biol. Chem. (1999) 274: 25260-25265.
41. USHER KC, BLASZCZAK LC, WESTON GS, SHOICHET BK, REMINGTON SJ: Three-dimensional structure of AmpC β-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry (1998) 37: 16082-16092.
42. LOBKOVSKY E, MOEWS PC, LIU H, ZHAO H, FRERE JM, KNOX JR: Evolution of an enzyme activity: crystallographic structure at 2-Å resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase.Proc. Natl. Acad. Sci. USA (1993) 90: 11257-11261.
43. POWERS RA, SHOICHET BK: Structure-based approach for binding-site identification on AmpC β-lactamase. J. Med. Chem. (2002) 45: 3222-3234.
44. PERNOT L, FRENOIS F, RYBKINE T et al.: Crystal structures of the class D β-lactamase OXA-13 in the native form and in complex with meropenem. J. Mol. Biol. (2001) 310: 859-874.
45. PAETZEL M, DANEL F, DE CASTRO L, MOSIMANN SC, PAGE MG, STRYNADKA NC: Crystal structure of the class D β-lactamase OXA-10. Nat. Struct. Biol. (2000) 7: 918-925.
46. MAVEYRAUD L, GOLEMI D, KOTRA LP et al.: Insights into class D β-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure Fold Des. (2000) 8 1289-1298.
47. MAVEYRAUD L, GOLEMI-KOTRA D, ISHIWATA A, MEROUEH O, MOBASHERY S, SAMAMA JP: High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 β-lactamase. J. Am. Chem. Soc. (2002) 124: 2461-2465.
48. SUN T, NUKAGA M, MAYAMA K, BRASWELL EH, KNOX JR: Comparison of β-lactamases of classes A and D: 1.5-Å crystallographic structure of the class D OXA-1 oxacillinase. Protein Sci. (2003) 12: 82-91.
49. GOLEMI D, MAVEYRAUD L, VAKULENKO S, SAMAMA JP, MOBASHERY S: Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases. Proc. Natl. Acad. Sci. USA (2001) 98: 14280-14285.
50. ORENCIA MC, YOON JS, NESS JE, STEMMER WP, STEVENS RC: Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol. (2001) 8: 238-242.
51. HALL BG, BARLOW M: Evolution of the serine β-lactamases: past, present and future. Drug Resist. Updat. (2004) 7: 111-123.
52. CARFI A, DUEE E, PAUL-SOTO R, GALLENI M, FRERE JM, DIDEBERG O: X-ray structure of the ZnII β-lactamase from Bacteroides fragilis in an orthorhombic crystal form. Acta Crystallogr. D. Biol. Crystallogr. (1998) 54 (Pt 1):45-57.
53. ULLAH JH, WALSH TR, TAYLOR IA et al.: The crystal structure of the L1 metallo-β-lactamase from Stenotrophomonas maltophilia at 1.7 A resolution. J. Mol. Biol. (1998) 284: 125-136.
54. SIMM AM, HIGGINS CS, CARENBAUER AL et al.: Characterization of monomeric L1 metallo-β-lactamase and the role of the N-terminal extension in negative cooperativity and antibiotic hydrolysis. J. Biol. Chem. (2002) 277: 24744-24752.
55. WANG Z, FAST W, VALENTINE AM, BENKOVIC SJ: Metallo-β-lactamase: structure and mechanism. Curr. Opin. Chem. Biol. (1999) 3: 614-622.
56. PAGE MI: The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases. Curr. Pharm. Des. (1999) 5: 895-913.
57. DAL PERARO M, VILA AJ, CARLONI P: Structural determinants and hydrogen-bond network of the mononuclear zinc(Ii)-β-lactamase active site. J. Biol. Inorg. Chem. (2002) 7: 704-712.
58. BUSH K, FREUDENBERGER J, SYKES RB: Inhibition of Escherichia coli TEM-2 β-lactamase by the sulfated compounds izumenolide, panosialin and sodium dodecyl sulfate. J. Antibiot. (1980) 33: 1560-1562.
59. ZHANG Z, PALZKILL T. Determinants of binding affinity and specificity for the interaction of TEM-1 and SME-1 β-lactamase with β-lactamase inhibitory protein. J. Biol. Chem. (2003) 278: 45706-45712.
60. MAITI SN, PHILLIPS OA, MICETICH RG, LIVERMORE DM: β-Lactamase inhibitors: agents to overcome bacterial resistance. Curr. Med. Chem. (1998) 5: 441-456.
61. PAGE MG: β-Lactamase inhibitors. Drug Resist. Updat. (2000) 3: 109-125.
62. HIGGINS PG, WISPLINGHOFF H, STEFANIK D, SEIFERT H: In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob. Agents Chemother. (2004) 48 1586-1592.
63. PRATT RF, LOOSEMORE MJ: 6β-bromopenicillanic acid, a potent β-lactamase inhibitor. Proc. Natl. Acad. Sci. USA (1978) 75: 4145-4149.
64. MELCHIOR NH, KEIDING J: In vitro evaluation of ampicillin/brobactam and comparison with other β-lactam antibiotics. J. Antimicrob. Chemother. (1991) 27: 29-40.
65. CHARNAS RL, KNOWLES JR: Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of enzyme with derivatives of olivanic acid. Biochemistry (1981) 20: 2732-2737.
66. MERCURI PS, ISHII Y, MA L et al.: Clonal diversity and metallo-β-lactamase production in clinical isolates of Stenotrophomonas maltophilia. Microb. Drug Resist. (2002) 8: 193-200.
67. CLARK NM, PATTERSON J, LYNCH JP 3rd: Antimicrobial resistance among Gram-negative organisms in the intensive care unit. Curr. Opin. Crit. Care. (2003) 9: 413-423.
68. LEVIN AS: Treatment of Acinetobacter spp. infections. Expert Opin. Pharmacother. (2003) 4: 1289-96.
69. FISHER J, CHARNAS RL, KNOWLES JR: Kinetic studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry (1978) 17: 2180-2184.
70. BRENNER DG, KNOWLES JR: 6-(Methoxymethylene)penicillanic acid: inactivator of RTEM β-lactamase from Escherichia coli. Biochemistry (1984) 23: 5839-5846.
71. BRENNER DG, KNOWLES JR: Penicillanic acid sulfone: nature of irreversible inactivation of RTEM β-lactamase from Escherichia coli. Biochemistry (1984) 23: 5833-5839.
72. CHEN CC, HERZBERG O: Inhibition of β-lactamase by clavulanate. Trapped intermediates in cryo-crystallographic studies. J. Mol. Biol. (1992) 224: 1103-1113.
73. MOOSDEEN F, KEEBLE J, WILLIAMS JD: Induction/inhibition of chromosomal β-lactamases by β-lactamase inhibitors. Rev. Infect. Dis. (1986) 8 (Suppl. 5):S562-S568.
74. CHAIBI EB, SIROT D, PAUL G, LABIA R: Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. (1999) 43: 447-458.
75. HELFAND MS, BETHEL CR, HUJER AM, HUJER KM, ANDERSON VE, BONOMO RA: Understanding resistance to β-lactams and β -lactamase inhibitors in the SHV β-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. (2003) 278: 52724-52729.
76. KAYE KS, GOLD HS, SCHWABER MJ et al.: Variety of β-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States. Antimicrob Agents Chemother. (2004) 48: 1520-1525.
77. PAGAN-RODRIGUEZ D, ZHOU X, SIMMONS R et al.: Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 → Gly SHV-1 β-lactamase: insights into the mechanism of inhibition. J. Biol. Chem. (2004) 279: 19494-19501.
78. BOU G, CERVERO G, DOMINGUEZ MA, QUEREDA C, MARTINEZ-BELTRAN J: Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J. Clin. Microbiol. (2000) 38: 3299-305.
79. NIKAIDO H: Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. (2003) 67: 593-656.
80. ESSACK SY, HALL LM, LIVERMORE DM: Klebsiella pneumoniae isolate from South Africa with multiple TEM, SHV and AmpC β -lactamases. Int. J. Antimicrob. Agents (2004) 23: 398-400.
81. TOLEMAN MA, ROLSTON K, JONES RN, WALSH TR: Molecular and biochemical characterization of OXA-45, an extended-spectrum class 2d′ β-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2003) 47: 2859-2863.
82. FINCH RG: Epidemiological features and chemotherapy of community-acquired respiratory tract infections. J. Antimicrob. Chemother. (1990) 26 (Suppl. E):53-61.
83. GULAY Z, BICMEN M, AMYES SG, YULUG N: β-Lactamase patterns and β-lactam/clavulanic acid resistance in Escherichia coli isolated from fecal samples from healthy volunteers. J. Chemother. (2000) 12: 208-215.
84. TREHAN I, MORANDI F, BLASZCZAK LC, SHOICHET BK: Using steric hindrance to design new inhibitors of class C β-lactamases. Chem. Biol. (2002) 9: 971-980.
85. POWERS RA, CASELLI E, FOCIA PJ, PRATI F, SHOICHET BK: Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: implications for resistance mutations and inhibitor design. Biochemistry (2001) 40: 9207-9214.
86. TREHAN I, BEADLE BM, SHOICHET BK: Inhibition of AmpC β-lactamase through a destabilizing interaction in the active site. Biochemistry (2001) 40: 7992-7999.
87. RICHTER HG, ANGEHRN P, HUBSCHWERLEN C et al.: Design, synthesis, and evaluation of 2β-alkenyl penam sulfone acids as inhibitors of β-lactamases. J. Med. Chem. (1996) 39: 3712-3722.
88. SANDANAYAKA VP, PRASHAD AS, YANG Y, WILLIAMSON RT, LIN YI, MANSOUR TS: Spirocyclopropyl β-lactams as mechanism-based inhibitors of serine β-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. J. Med. Chem. (2003) 46: 2569-2571.
89. BUYNAK JD, DOPPALAPUDI VR, ADAM G: The synthesis and evaluation of 3-substituted-7-(alkylidene)cephalosporin sulfones as β-lactamase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10: 853-857.
90. BUYNAK JD, DOPPALAPUDI VR, RAO AS, NIDAMARTHY SD, ADAM G: The synthesis and evaluation of 2-substituted-7-(alkylidene)cephalosporin sulfories as β-lactamase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10: 847-851.
91. JACOBY GA, MILLS DM, CHOW N: Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2004) 48: 3203-3206.
92. CRICHLOW GV, NUKAGA M, DOPPALAPUDI VR, BUYNAK JD, KNOX JR: Inhibition of class C β-lactamases: structure of a reaction intermediate with a cephem sulfone. Biochemistry (2001) 40: 6233-6239.
93. BUYNAK JD, CHEN H, VOGETI L et al.: Penicillin-derived inhibitors that simultaneously target both metallo- and serine-β-lactamases. Bioorg. Med. Chem. Lett. (2004) 14: 1299-1304.
94. SIMPSON IN, URCH CJ, HAGEN G, ALBRECHT R, SPRINKART B, PFAENDLER HR: Synthesis and biological activity of AM-112 and related oxapenem analogues. J. Antibiot. (2003) 56: 838-847.
95. JAMIESON CE, LAMBERT PA, SIMPSON IN: In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. (2003) 47: 2615-2618.
96. JAMIESON CE, LAMBERT PA, SIMPSON IN: In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrob. Agents Chemother. (2003) 47: 1652-1657.
97. ARISAWA M, THEN RL: 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent β-lactamase inhibitor. I. Inhibition of chromosomally and R-factor-mediated β-lactamases. J. Antibiot. (1982) 35: 1578-1583.
98. ANGEHRN P, ARISAWA M: 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent β-lactamase inhibitor. II. Antibacterial properties. J. Antibiot. (1982) 35: 1584-1589.
99. COLEMAN K, GRIFFIN DR, PAGE JW, UPSHON PA: In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob. Agents Chemother. (1989) 33: 1580-1587.
100. COLEMAN K, GRIFFIN DR, UPSHON PA: Pharmacokinetic studies and renal dehydropeptidase stability of the new β-lactamase inhibitor BRL 42715 in animals. Antimicrob. Agents Chemother. (1991) 35: 1748-1752.
101. NUKAGA M, ABE T, VENKATESAN AM, MANSOUR TS, BONOMO RA, KNOX JR. Inhibition of class A and class C β-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate. Biochemistry (2003) 42: 13152-13159.
102. HUBSCHWERLEN C, ANGEHRN P, GUBERNATOR K, PAGE MG, SPECKLIN JL: Structure-based design of β-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins. J. Med. Chem. (1998) 41: 3972-3975.
103. HEINZE-KRAUSS I, ANGEHRN P, CHARNAS RL et al.: Structure-based design of β-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams. J. Med. Chem. (1998) 41: 3961-3971.
104. NISHIDA K, KUNUGITA C, UJI T et al.: In vitro and in vivo activities of Syn2190, a novel β-lactamase inhibitor. Antimicrob Agents Chemother. (1999) 43: 1895-1900.
105. BEESLEY T, GASCOYNE N, KNOTT-HUNZIKER V et al.: The inhibition of class C β-lactamases by boronic acids. Biochem. J. (1983) 209: 229-233.
106. TONDI D, POWERS RA, CASELLI E et al.: Structure-based design and in-parallel synthesis of inhibitors of AmpC β-lactamase. Chem. Biol. (2001) 8: 593-611.
107. POWERS RA, BLAZQUEZ J, WESTON GS, MOROSINI MI, BAQUERO F, SHOICHET BK: The complexed structure and antimicrobial activity of a non-β-lactam inhibitor of AmpC β-lactamase. Protein Sci. (1999) 8: 2330-2337.
108. NESS S, MARTIN R, KINDLER AM et al.: Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 β-lactamase. Biochemistry (2000) 39: 5312-5321.
109. RAHIL J, PRATT RF: Mechanism of inhibition of the class C β-lactamase of Enterobacter cloacae P99 by phosphonate monoesters. Biochemistry (1992) 31: 5869-5878.
110. CHEN CC, RAHIL J, PRATT RF, HERZBERG O: Structure of a phosphonate-inhibited β-lactamase. An analog of the tetrahedral transition state/intermediate of β-lactam hydrolysis. J. Mol. Biol. (1993) 234: 165-178.
111. LOBKOVSKY E, BILLINGS EM, MOEWS PC, RAHIL J, PRATT RF, KNOX JR: Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a β-lactamase transition-state analog. Biochemistry (1994) 33: 6762-6772.
112. KAUR K, ADEDIRAN SA, LAN MJ, PRATT RF: Inhibition of β-lactamases by monocyclic acyl phosph(on)ates. Biochemistry (2003) 42: 1529-1536.
113. ABOU-KHALIL E, BEAULIEU C, BERNSTEIN N et al.: Sulfonamidomethylphosphonates: novel non-β-lactam β-lactamase inhibitors. Intersci. Conf. Antimicrob. Agents Chemother. (2001) Abstract F-387.
114. TRIAS J, NIKAIDO H: Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1990) 34: 52-57.
115. SATAKE S, YONEYAMA H, NAKAE T: Role of OmpD2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J. Antimicrob. Chemother. (1991) 28: 199-207.
116. LIVERMORE DM: Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1992) 36: 2046-2048.
117. YONEYAMA H, NAKAE T: Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1993) 37: 2385-2390.
118. OKAMOTO K, GOTOH N, NISHINO T: Alterations of susceptibility of Pseudamonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J. Infect. Chemother. (2002) 8: 371-373.
119. OKAMOTO K, GOTOH N, NISHINO T: Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2002) 46: 2696-2699.
120. MASUDA N, SAKAGAWA E, OHYA S, GOTOH N, TSUJIMOTO H, NISHINO T: Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2000) 44: 3322-3327.
121. LI XZ, ZHANG L, POOLE K: Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. (2000) 45: 433-436.
122. PERRON K, CAILLE O, ROSSIER C, VAN DELDEN C, DUMAS JL, KOHLER T: CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J. Biol. Chem. (2004) 279: 8761-8768.
123. ZHANG L, LI XZ, POOLE K: Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob. Agents Chemother. (2000) 44: 287-293.
124. POOLE K: Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J. Mol. Microbiol. Biotechnol. (2001) 3: 255-264.
125. CHAN YY, TAN TM, ONG YM, CHUA KL: BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob. Agents Chemother. (2004) 48: 1128-1135.
126. ARPIN C, LABIA R, DUBOIS V, NOURY P, SOUQUET M, QUENTIN C: TEM-80, a novel inhibitor-resistant β-lactamase in a clinical isolate of Enterobacter cloacae. Antimicrob. Agents Chemother. (2002) 46 1183-1189.
127. NAAS T, ZERBIB M, GIRLICH D, NORDMANN P: Integration of a transposon Tn1-encoded inhibitor-resistant β-lactamase gene, bla(TEM-67) from Proteus mirabilis, into the Escherichia coli chromosome. Antimicrob. Agents Chemother. (2003) 47: 19-26.
128. BONNEFOY A, DUPUIS-HAMELIN C, STEIER V et al.: In vitro activity of AVE1330A, an innovative broad-spectrum non-β -lactam β-lactamase inhibitor. J. Antimicrob. Chemother. (2004) 54: 410-417.